Literature DB >> 8625095

p53 expression in dedifferentiated chondrosarcoma.

W W Simms1, N G Ordóñez, D Johnston, A G Ayala, B Czerniak.   

Abstract

BACKGROUND: p53 acts as a tumor suppressor gene because of to its negative control of the cell cycle and its central role in programmed cell death. It frequently is mutated, as observed in a variety of human neoplasms. The mutations inhibit tumor-suppressor activities of p53, which may gain a new function of tumor promotion. In this study, p53 was investigated in various components of dedifferentiated chondrosarcoma and correlated with their proliferative activities.
METHODS: Immunohistochemical assays for p53, Ki-67, and proliferating cell nuclear antigen (PCNA) were used in a series of eight dedifferentiated chondrosarcomas of bone. The cartilaginous component was low grade (Grade I-II) in five cases. It was predominantly low grade with foci of a high grade (Grade III) chondrosarcoma in the remaining three cases. The noncartilaginous (dedifferentiated) high grade component consisted of malignant fibrous histiocytoma in five cases and osteosarcoma in three.
RESULTS: Regardless of the histological type, diffuse strong nuclear staining for p53 occurred in the high grade noncartilaginous component of all eight of the tumors. The low grade cartilaginous component of six cases was negative for p53, with focal weak staining in the two remaining cases. The high grade cartilaginous component showed strong positive staining for this protein in all three cases. Ki-67 and PCNA expression were similar to that of p53.
CONCLUSIONS: The percentage of p53 positive staining roughly was parallel to the proliferating fraction of cells in various components of dedifferentiated chondrosarcoma. Moreover, p53 overexpression was consistently present in the high grade noncartilaginous (dedifferentiated) component of the tumor and was accompanied by increased proliferative activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8625095     DOI: 10.1002/1097-0142(19950715)76:2<223::aid-cncr2820760210>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.

Authors:  R Schneider-Stock; K Radig; Y Oda; W Mellin; J Rys; A Niezabitowski; A Roessner
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 2.  Molecular pathology of chondroid neoplasms: part 2, malignant lesions.

Authors:  W C Bell; M J Klein; M J Pitt; G P Siegal
Journal:  Skeletal Radiol       Date:  2006-10-18       Impact factor: 2.199

Review 3.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

4.  Dedifferentiated peripheral chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of four cases.

Authors:  Alessandro Franchi; Gianna Baroni; Iacopo Sardi; Laura Giunti; Rodolfo Capanna; Domenico Campanacci
Journal:  Virchows Arch       Date:  2012-02-16       Impact factor: 4.064

5.  Chondrosarcoma cell differentiation.

Authors:  Joseph G Sinkovics
Journal:  Pathol Oncol Res       Date:  2004-09-25       Impact factor: 3.201

6.  A case of dedifferentiated solitary fibrous tumor in the pelvis with TP53 mutation.

Authors:  Aiko Kurisaki-Arakawa; Keisuke Akaike; Kieko Hara; Atsushi Arakawa; Michiko Takahashi; Keiko Mitani; Takashi Yao; Tsuyoshi Saito
Journal:  Virchows Arch       Date:  2014-11       Impact factor: 4.064

7.  Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute.

Authors:  Kazuya Yokota; Akio Sakamoto; Yoshihiro Matsumoto; Shuichi Matsuda; Katsumi Harimaya; Yoshinao Oda; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2012-12-10       Impact factor: 2.359

8.  Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation.

Authors:  Naoko Kudo; Akira Ogose; Tetsuo Hotta; Hiroyuki Kawashima; Wenguang Gu; Hajime Umezu; Tsuyoshi Toyama; Naoto Endo
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.535

9.  Prognostic markers in chondrosarcoma: evaluation of cell proliferation and of regulators of the cell cycle.

Authors:  S P Scully; L J Layfield; J M Harrelson
Journal:  Sarcoma       Date:  1997

10.  The molecular pathogenesis of dedifferentiated chondrosarcoma.

Authors:  Akio Sakamoto
Journal:  Indian J Orthop       Date:  2014-05       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.